RxDoctor Payments Data

Daniel Carothers, MD

Otolaryngology · Atlanta, GANPI 1730116161

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (49.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Optinose US, Inc. at 51.3% of the total. Reporting peaked in 2019 at $4,194 and has fallen 77.2% since, to $956 in 2025. Among otolaryngology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,993in general payments, 2019–2025

Across 165 payments — averaging $48.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$4K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Sanofi$896
  • Stryker$732
  • Intersect ENT, Inc.$207
  • Kaleo, Inc.$175
  • plus $871 from 13 others

What the payments were for

  • Consulting fees$3,00038%
  • Travel & lodging$95912%
  • Food & beverage$3,98550%
  • Education$491%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,993 in reported general payments places this provider in the 95th percentile of 308 otolaryngology providers in Georgia.

See all otolaryngology providers in Georgia

Medicare billing

Part B allowed, 2024
$135,246
Medicare patients
259
Services billed
1,225

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab36$134,410
RyaltrisOlopatadine Hcl/Mometasone11$2,617
Ipratropium Bromide100$2,606
Fluticasone Propionate90$1,247
Famotidine150$1,029
Azelastine Hcl24$948
Pantoprazole Sodium117$818
Omeprazole35$591
Doxycycline Monohydrate50$522
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav34$249
Methylprednisolone47$213
Ondansetron OdtOndansetron26$165
Mometasone Furoate24$141
Albuterol Sulfate HfaAlbuterol Sulfate16$93
Prednisone27$87

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USARyaltris$91$2,61711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 otolaryngology providers in Georgia.

Other otolaryngology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →